Introduction: The levels and distribution of amyloid deposits in the brain does not correlate well with Alzheimer's disease (AD) progression. Therefore, it is likely that amyloid precursor protein and its proteolytic fragments other than amyloid b (Ab) contribute to the onset of AD.
Introduction
Alzheimer's disease (AD) is the most common type of dementia, characterized by accumulation of extracellular and intracellular amyloid b (Ab) aggregates, intracellular paired helical fragments and extensive age-dependent neuronal loss in vulnerable areas [1] [2] [3] . Robust genetic and biochemical evidence points to alterations of amyloid precursor protein (APP) metabolism as causative in the development of AD.
In the amyloidogenic pathway, APP is cleaved by bsecretase (BACE) to generate soluble APP beta protein (sAPPb) and C99. g-secretase then cleaves C99 to generate Ab and amyloid precursor protein intracellular domain (AICD). Accumulation of Ab is a cardinal feature of AD, but its role in causing injury in AD remains unclear. Thus, the distribution of Ab deposits in AD brains has a poor correlation with dementia severity, loss of neural function, and cognitive impairment [4] [5] [6] [7] [8] [9] . Therefore, it is possible that APP metabolites other than Ab make a significant contribution to AD pathophysiology. In addressing this issue, a challenge has been the inability to determine the distribution and levels of specific APP metabolites in intact cells and tissues. We have approached this problem by adapting the proximity ligation assay (PLA) for the detection of C99. In this assay, two primary antibodies recognize the target epitopes on the protein of interest. If the epitopes are in close proximity, secondary antibodies covalently bound to complementary DNA strands participate in rolling circle DNA synthesis. The DNA synthesis reaction results in a one thousand-fold amplification of the DNA circle. Fluorescently labeled complementary oligonucleotide probes added to the reaction bind to the amplified DNA. The resulting fluorescent signal can be detected by fluorescence microscopy. This technique offers great sensitivity because powerful rolling circle amplification is used. It also offers great selectivity because dual target recognition is used [10, 11] . Here, we used antibodies generated against both the N and C terminal domains of C99 in cultured cells and found that we can distinguish C99 from Ab, full-length APP, C83, and AICD. The adaptation of the proximity ligation assay for the detection of C99 provides a general framework for the detection in situ of low-abundance proteolytic fragments in the human brain and animal models.
Materials and methods

Antibodies
Primary antibodies used were anti-NeuN, Millipore; anti-GFAP, Abcam; anti-N-terminal C99, 6C3, Abcam, anti-Tau AF3494, R&D, anti-Ab 6E10, Covance, and RU-369 produced at the Rockefeller University. Secondary antibody was AlexaFluor 488 from Molecular Probes.
PLA in cells
N2A cells stably overexpressing APP-695 were cultured in a DMEM medium (Gibco, catalog number 11965-092), Opti-MEM (Gibco, catalog number 51985-034), supplemented with 5% FBS (Sigma, catalog number F4135), 100 ug/ml of Penicillin/Streptomycin (Gibco, catalog number 15140-122) and 500 ug/ml Geneticin (Gibco, catalog number 10131-027). Twenty thousand cells were seeded in 12 mm glass coverslips (Corning Inc., catalog number 354085) in a 12-well plate and allowed to attach for 24 hrs. Next, cells were incubated overnight with 5 mM BACE inhibitor IV (MilliporeSigma, catalog number 565788) or 1 mM g-secretase inhibitor L-685,458 (Sigma, catalog number L1790) or DMSO (Sigma, catalog number 276855) 0.1% as a control.
Next day, the cells were washed with phosphate-buffered saline (PBS), fixed in 4% paraformaldehyde in PBS for 10 min at room temperature, permeabilized in PBS with 0.2 % Triton X-100 (PBST) for 10 min, blocked in 10% goat serum in PBST, and incubated in a primary antibody overnight in a blocking solution. Primary antibodies used to recognize C99 were RU-369 (Immune serum raised in rabbit, 1:50 dilution) and 6C3 (Abcam, catalog number 126649 raised in mouse, 1:50 dilution). Next, the Duolink kit was used to develop the PLA signal (Sigma, catalog number DUO92008). Briefly, cells were then washed twice for 10 min each time in wash buffer A, incubated with PLA probe solution for 1 h at 37 C, washed again in wash buffer A, and incubated in ligation-ligase solution for 30 min at 37 C. Coverslips were washed in wash buffer A, incubated in amplification-polymerase solution for 100 min at 37 C, and washed twice for 10 min each time in wash buffer B. Next, the coverslips were mounted in Duolink mounting media with 4 0 ,6-diamidino-2-phenylindole (DAPI). The specificity of the signal was controlled by omitting one of the antibodies. Cells were imaged using a Zeiss LSM710 laser confocal microscope. Quantification of the PLA signal was performed using Image J software (NIH).
N2a cells stably overexpressing APP-695 were seeded on a sterile, Zeiss high-performance cover glass at a density of 175,000 cells/well and grown overnight. Cells were treated with dimethyl sulfoxide (DMSO) or a g-secretase inhibitor (1 mM) in media for 3 hours. Cells were fixed with 4% PFA in PBS for 10 min at room temperature, permeabilized with PBST for 10 min at room temperature, and blocked in DuolinkÒ PLA blocking solution for 1 hour at 37 C. The cells were then incubated with primary antibodies RU-369 and 6C3, both at a 1:50 dilution in the DuolinkÒ antibody diluent, overnight at 4 C. PLA was conducted the next day using the DuolinkÒ PLA kit in accordance with the manufacturer's instructions until the mounting step in which the cells were separately stained for DAPI and then mounted onto a glass slide using a VECTASHIELDÒ antifade mounting medium without DAPI (Vector, catalog number H-1000). Coverslips were sealed with metallic nail polish and stored in the dark at 4 C until imaging. Super resolution three-dimensional images were captured using a DeltaVision OMXÔ microscope in structured illumination mode. Lasers (568 nm and 405 nm) were used to image DAPI and PLA. The camera temperature was kept at 280 C, chamber temperature was kept at 23 C, and an immersion oil with a refractive index of 1.515 was used. Z-stacks were taken to include all visible PLA dots and nuclei on the coverslip. The image data acquired by DeltaVision OMX was then reconstructed using softWoRx imaging workstation. Linespacing, best fit for K0, and amplitude values were evaluated to ensure the quality of the reconstruction. The reconstruction was then subjected to further processing by the "OMX Align Image" function. The version of the final image was then compared with a widefield version of the same image using the "Generate Widefield" and "Deconvolve" functions on the raw nonreconstructed data. Individual sections from the total z-stack were used for comparison.
Proximity ligation assay in human brain sections
Forty-nine human brain slides from the hippocampus, frontal cortex, and occipital cortex were obtained from the brain bank at Mount Sinai/JJ Peters VA Medical Center NIH Brain and Tissue Repository. Donors were selected to evidence no neuropathology or only the neuropathology of AD excluding any other discernable neuropathology, such as cerebrovascular disease or Lewy bodies. Before proceeding with the staining protocol, the slides were deparaffinized and rehydrated. Slides were placed in a rack, and the following washes were performed: (1) xylene: 2 ! 3 minutes, (2) xylene 1:1 with 100% ethanol: 3 minutes, (3) 100% ethanol: 2 ! 3 minutes (4) 95% ethanol: 3 minutes, (5) 70 % ethanol: 3 minutes, and (6) 50 % ethanol: 3 minutes. At the end of the washes, the brain slides were rinsed with water. Antigen retrieval was performed by microwaving the slides for 20 min in citric buffer, pH 6.0. Next, the slides were permeabilized in PBST for 10 min, blocked in 10% goat serum in PBST, and incubated in primary antibody overnight in blocking solution. Primary antibodies used to recognize C99 were RU-369 (Immune serum raised in rabbit, 1:50 dilution) and 6C3 (Abcam, catalog number 126649 raised in mice, 1:50 dilution). Next, the Duolink kit was used to develop the PLA signal (Sigma, catalog number DUO92008). Cells were then washed twice for 10 min each time in wash buffer A, incubated with a PLA probe solution for 1 h at 37 C, washed again in wash buffer A, and incubated in ligation-ligase solution for 30 min at 37 C. Coverslips were washed in wash buffer A, incubated in an amplification-polymerase solution for 100 min at 37 C, and washed twice for 10 min each time in wash buffer B. Next, the slides were incubated with 0.001% DAPI in 0.01% wash buffer B for 5 min. Then, to quench autofluorescence, the slides were treated with TrueBlack (Biotium, catalog number 23007) in 70% ethanol for 1 min. and subsequently mounted using Fluoromount-G (Southern Biotech). Slides were imaged using a Zeiss LSM710 laser confocal microscope. For coimmunofluorescence of C99-PLA with neuron and astrocyte markers, as well as with tau protein, respective antibodies were used together with C99 primary antibodies and secondary antibodies together with PLA probes.
PLA quantification
C99-PLA produces bright red dots that were quantified using the Image J software (NIH). The tiff images were thresholded, and the function "Analyze particles" was applied in the red channel. In the blue channel, corresponding to DAPI staining, the function "Cell counter" was applied after threshold.
OMX 3D-SIM using DeltaVision OMX
N2a695 cells were seeded on sterile, high-performance Zeiss cover glass at a density of 175,000 cells/well and grown overnight. The cells were treated with DMSO or a g-secretase inhibitor (1 mM) in media for 3 hours. The cells were fixed with 4% PFA in PBS and then permeabilized with PBST. The cells were blocked for 1 hour in DuolinkÒ PLA blocking solution at 37 C. The cells were then incubated with primary antibodies APP369 and C99, both at a 1:50 dilution in the DuolinkÒ antibody diluent, overnight at 4 C. PLA was conducted the next day using the DuolinkÒ PLA kit in accordance with the manufacturer's instructions until the mounting step in which the cells were separately stained for DAPI and then mounted onto a glass slide using a VECTASHIELDÒ antifade mounting medium without DAPI. Coverslips were sealed with metallic nail polish and stored in the dark at 4 C until imaging. Super resolution three-dimensional images were captured using a DeltaVision OMXÔ microscope in structured illumination mode. 568 nm and 405 nm lasers were used to image DAPI and PLA. The camera temperature was kept at 280 C, the chamber temperature was kept at 23 C, and an immersion oil with a refractive index of 1.515 was used. Z-stacks were taken to include all visible PLA dots and nuclei on the coverslip. The image data acquired by the DeltaVision OMX microscope were then reconstructed using softWoRx imaging workstation. Linespacing, best fit for K0, and amplitude values were evaluated to ensure the quality of the reconstruction. The reconstruction was then subjected to further processing by the OMX Align Image function. The final image was then compared with a widefield version of the same image using the generate widefield and deconvolve functions on the raw nonreconstructed data. Individual sections from the total zstack were used for comparisons.
Amyloid plaque staining
Sections from paraffin-embedded blocks were stained using hematoxylin-eosin and anti-b amyloid 4G8 and anti-tau AD2. All neuropathologic data regarding the extent and distribution of neuropathologic lesions were collected by neuropathologists unaware of any of the clinical and psychometric data.
For quantitative measures of plaque density, 5 representative high-power fields (0.5 mm 2 ) were examined and an average density score was calculated for each region and expressed as mean plaque density per square millimeter. When plaques were unevenly distributed in each slide, plaques in the region with the highest density were counted. These sections were adjacent to the sections used to quantify C99 levels.
Statistical analysis
The data are presented as means 6 SD. The significance level was determined using a two-way ANOVA with the Bonferroni post-test, comparing severe versus nondemented control, moderate versus nondemented control, and severe versus moderate. Multiple regression analysis (Fig. 4B ) was performed using the SPSS statistical package from IBM. Other statistical analyses were performed by using GraphPad Prism software.
Results
First, we screened several antibodies aimed at recognizing the N-and C-terminal domains of C99. The combination of 6C3, a mouse monoclonal antibody [12] which recognizes the cleaved N-terminal of C99 and RU-369, a rabbit polyclonal antibody [13] designed to recognize the Cterminal of APP, successfully recognized C99 (Fig. 1A) . As expected with a C99-specific marker, the signal was greatly reduced by a BACE inhibitor, which blocks C99 synthesis, and dramatically increased by a g-secretase inhibitor, which blocks C99 breakdown (Fig. 1B) . To further exclude the possibility that the 6C3 antibody recognizes full length APP, we performed double immunofluorescence with 6C3 and RU-369 in N2a-695 cells treated with DMSO, BACE inhibitor, or g-secretase inhibitor. The signal from 6C3 was reduced upon treatment with a BACE inhibitor and increased upon treatment with g-secretase inhibitor, suggesting that 6C3 de-tects C99 and not APP full length. In addition, Western blot analysis indicated that 6C3 recognized only C99 and not APP full length. ( Supplementary Fig. 1 ). C99-PLA produces bright red dots that can easily be quantified. Super-resolution microscopy revealed that each dot, measuring about 200-400 nm, consisted of a group of 2-3 smaller dots, consistent with the idea of aggregation of C99 molecules (Fig. 1C) .
Next, we applied this PLA methodology to study the localization of C99 in the human-brain tissue. Brain tissue sections were obtained from the hippocampus, frontal cortex, and occipital cortex from 12 controls and 37 patients suffering from sporadic AD. Age at the time of death, sex, Braak stage, Thai, and the CERAD score of these subjects is listed in Supplementary Table 1 . PLA specificity was verified by omitting one of the antibodies ( Supplementary  Fig. 2 ). As seen in Fig. 2A , C99 is readily detected in the soma and processes of neurons of cognitively normal patients.
To investigate whether C99 levels correlate with cognitive decline, three postmortem groups were studied: patients with normal and stable cognition, as measured by the clinical dementia rating (Clinical Dementia Rating 5 0); patients with moderate AD (Clinical Dementia Rating 5 0.5-2); and patients with severe AD (Clinical Dementia Rating 5 3-5). Average C99 levels were increased in the CA1 area of the hippocampus when comparing patients with severe AD with nondemented controls (39.8 6 11.8 vs. 12.5 6 4.1 [PLA dots/cell], P ,.001), patients with moderate AD with controls (28.3 6 6.4 vs. 12.5 6 4.1, P ,.001), or patients with severe AD with patients with moderate AD (39.8 6 11.8 vs. 28.3 6 6.4, P ,.05) ( Fig. 2A, E) . In the dentate gyrus area, C99 levels were increased when comparing patients with severe AD with nondemented controls (10.8 6 2.8 vs. 2.5 6 1.1, P , .001), patients with moderate AD with nondemented controls (6.5 6 2.4 vs. 2.5 6 1.1, P ,.05), and patients with severe AD with patients with moderate AD (10.8 6 2.8 vs. 6.5 6 2.4) (Fig. 2B, E) . In the middle frontal gyrus of the frontal cortex, C99 levels were increased when comparing patients with severe AD with controls (7.1 6 2.0 vs. 2.3 6 1.6, P , .001) and patients with severe AD with patients with moderate AD (7.1 6 2.0 vs. 2.60 6 1.6, P , .001) (Fig. 2C, E) . Levels of C99 in the occipital cortex, an area considered to be resistant to neurodegeneration, were similar in all three groups (Fig. 2D, E) . Four additional samples from the hippocampus of nondemented patients and patients with severe AD were subjected to Western blot analysis using the antibody 6E10. An increase of 4.5 times in C99 levels was observed when comparing patients with severe AD with nondemented controls, comparable to the increase seen by PLA ( Supplementary Fig. 3 )
Co-staining with the neuronal nuclear marker NeuN showed that C99 accumulated in the perinuclear region of neurons in nondemented patients. Its distribution changed to an intranuclear pattern in patients with AD in the dentate gyrus and frontal cortex ( Fig. 3A and C) . Interestingly, C99 also accumulated in astrocytes in patients with AD, where it was localized in both the soma and processes, as revealed by glial fibrillary acidic protein (GFAP) staining. However, in contrast to neurons, the distribution of C99 in astrocytes did not change between nondemented and demented patients ( Fig. 3B and C) . Next, we compared the levels of Ab plaques and C99 in the middle frontal cortex and occipital cortex. As seen in Fig. 4A and B , Ab plaques were present in both vulnerable and nonvulnerable areas, whereas C99 accumulation was correlated with disease progression only in the middle frontal cortex, a vulnerable area, but not in the occipital cortex, a resistant area. To study the association of C99 with selective neuronal vulnerability, co-staining with tau was performed in the CA1 area of 7 nondemented controls and 15 patients with AD. As seen in Fig. 4C and D, C99 levels were greatly increased in neurons with high levels of tau, which is a widely accepted marker of neuronal vulnerability. These results show that C99 accumulation, as opposed to Ab plaques, is specific to neurons most vulnerable to neurodegeneration in AD.
Discussion
AD is characterized by accumulation of amyloid plaques and paired helical filaments. Mutations that cause earlyonset AD are located in the genes that code for the APP and the enzyme responsible for amyloid production, Presenilin 1/Presenilin 2. These observations have led to the widely-held belief that Ab has a causative role in the development of AD. However, the distribution of amyloid deposits in the brain does not correlate well with disease progression. These results suggest the possibility that APP metabolites other than Ab might contribute to AD. It has been proposed that C99, a specific APP metabolite, may cause neurodegeneration by inducing endosomal enlargement [14, 15] , leading to endosomal dysfunction and neuronal death [16] [17] [18] [19] .
In this study, we have developed a method to detect C99 in situ and applied this method to measure the levels of C99 in postmortem human-brain samples of individuals at different stages of AD dementia. We found a correlation between levels of C99 and levels of cognitive decline in areas vulnerable to neurodegeneration, such as the hippocampus and frontal cortex. In the hippocampus, we found increased levels of C99 in the CA1 area and dentate gyrus in both moderate and severe AD, whereas in the frontal cortex, we found increased levels of C99 only in severe cases of AD, consistent with the well-established delayed involvement of the frontal cortex in AD pathology. This correlation was absent in areas resistant to neurodegeneration, such as the occipital cortex. In contrast to the area-specific increase in C99 levels, all areas studied in patients with AD presented abundant amyloid plaques. Further work is required to understand the underlying mechanism by which C99 accumulates in the vulnerable areas of the brain. C99 may accumulate as a consequence of increased synthesis or decreased degradation. Several studies show elevated BACE activity in sporadic AD [20] [21] [22] , which could account for elevation of C99 levels due to increased synthesis. On the other hand, we and others have shown that C99 is degraded through autophagy and the endosomal-lysosomal pathway [23] [24] [25] [26] [27] , failure of which could account for a reduced degradation. Elucidation of the detailed molecular pathway that leads to the synthesis and breakdown of C99 is likely to reveal targets responsible for the regulation of this metabolite. Such information may greatly accelerate the development of therapeutic agents for the treatment of AD.
One limitation of the method described here is that it recognizes only one type of APP b-C-terminal fragment product of BACE cleavage. BACE 1 cleaves APP between Met671 and Asp672 to generate the carboxyl-terminal fragment C99. BACE1 also cleaves APP between Thr681 and Gln682, yielding C89 [28] . Our method is specific for C99, and it cannot detect C89. In regard to Ab levels, the method used detects Ab plaques, and it is possible that selected Ab species may correlate with neuronal vulnerability. Another limitation of the present study is the relatively small sample size, which allowed us to draw correlations between C99 and amyloid levels with cognitive decline, but prevented us from evaluating the correlation of C99 levels with Braak staging.
Using a new method to detect specific APP metabolites, we show that C99 accumulates selectively in vulnerable neurons, but not in resistant neurons, in the brains of patients with AD. Approaches to reduce amyloid burden, such as g-secretase inhibitors or immunotherapy, despite being successful at reducing Ab levels, have failed to stop or reduce the cognitive impairment that characterizes AD. Semagacestat, a g-secretase inhibitor, worsened the symptoms of dementia in a large phase III clinical trial [29] . It was speculated that this action might have been due to inhibition of the cleavage by g-secretase of other substrates such as Notch. We suggest here that the clinical failure may have been due, at least in part, to the accumulation of C99.
The results shown here add to growing evidence that C99 accumulation in vulnerable neurons contributes to neuronal death in AD [14, 15, 17, 18, [30] [31] [32] [33] 34] . The question arises as to how C99 induces neuronal death.
Dysfunction of the endosomal-lysosomal and autophagic pathways are one of the earliest key events in AD, progressing to widespread failure of intraneuronal waste clearance, leading to neuritic dystrophy and finally to neuronal cell death. It has been shown that elevated levels of C99 in fibroblasts from Down syndrome and AD induce endosomal dysfunction by increasing the recruitment of APPL1 to Rab5 endosomes, where it stabilizes active GTP-Rab5, leading to accelerated endocytosis, endosome swelling, and impaired axonal transport of Rab5 endosomes [14, 15] . It will be interesting to see the specific sites of C99 accumulation in the human brain (for instance, using PLA and various vesicle markers) and the effect of such accumulation on the endosomal-lysosomal and autophagic pathways in human neurons in culture. It has also been shown that C99 accumulation in the mouse brain leads to an increase in vesicles positive for Cathepsin B and Lamp1, as well as increased levels of LC3II and autophagic dysfunction [17] . Although the exact molecular mechanism by which C99 exerts this effect is not yet known, it is becoming clear that C99 accumulation contributes to neuronal dysfunction and ultimately to neuronal death.
Our results show a correlation between C99 levels and cognitive impairment. It has been previously found that synaptic loss is the major correlate of cognitive impairment [4] . To analyze the relationship of C99 with synaptic loss, it could be possible to measure synaptic markers like SNAP25 and synaptophysin [35] , in both vulnerable and resistant brain areas and correlate them with C99 levels.
The method that we developed to detect specific APP fragments in fixed brain slides can be modified to quantify APP metabolites in human fluids. To that end, it could be possible to quantify C99 levels in plasma and CSF and correlate them with cognitive deterioration and vulnerability to neurodegeneration, with the goal of developing C99 as an AD biomarker.
In conclusion, our results raise the possibility that C99, rather than Ab, is responsible for the death of nerve cells in AD. In that case, b-secretase inhibitors, which lower both C99 and Ab, are preferable to g-secretase inhibitors, which lower Ab but increase C99 levels.
